Project aims to digitally design pharmaceutical processes
02 February 2016
A newly formed collaborative project aims to transform the UK pharmaceutical industry by enabling the manufacturing processes of medicines of the future to be designed digitally.
The ADDoPT (Advanced Digital Design of Pharmaceutical Therapeutics) project addresses a key challenge for the pharmaceutical industry – that of getting new medicines to market in the quickest and most cost-effective way possible to ensure access for patients. The collaborative project will pursue this goal by developing and implementing advanced digital design techniques that eliminate non-viable drug candidate formulations as early as possible, streamlining design, development and manufacturing processes.
ADDoPT draws on the expertise of UK technology and academic leaders in the field of digital design concepts . One member is Perceptive Engineering, which has specific expertise in data-driven process modelling, monitoring, predictive control and optimisation. The company’s experience will be applied to industrial case studies provided by Pfizer, GSK, AstraZeneca and Bristol-Myers Squibb within the consortium. A key objective is to achieve better design and scale-up for robust products and processes through more targeted future experimentation and better understanding of risk.
ADDoPT will include big data, mechanistic modelling, process optimisation and control to establish a competitive knowledge value supply chain for the pharmaceutical sector. Project lead, Sean Bermingham of Process Systems Enterprise said, “By building on excellence in process modelling, optimisation and control, we can give UK pharmaceutical development and manufacturing a genuine competitive advantage in this globally significant sector.
Most Viewed Articles...